Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 131

1.

Prevention of implantable-defibrillator shocks by treatment with sotalol. d,l-Sotalol Implantable Cardioverter-Defibrillator Study Group.

Pacifico A, Hohnloser SH, Williams JH, Tao B, Saksena S, Henry PD, Prystowsky EN.

N Engl J Med. 1999 Jun 17;340(24):1855-62.

2.

Risk stratification and clinical outcome of minimally symptomatic and asymptomatic patients with nonsustained ventricular tachycardia and coronary disease: a prospective single-center study.

Giorgberidze I, Saksena S, Krol RB, Munsif AN, Kolettis T, Mathew P, Varanasi S, Prakash A, Delfaut P, Lewis CB.

Am J Cardiol. 1997 Sep 11;80(5B):3F-9F.

PMID:
9291444
4.

Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.

Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, Domanski M, Troutman C, Anderson J, Johnson G, McNulty SE, Clapp-Channing N, Davidson-Ray LD, Fraulo ES, Fishbein DP, Luceri RM, Ip JH; Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators.

N Engl J Med. 2005 Jan 20;352(3):225-37. Erratum in: N Engl J Med. 2005 May 19;352(20):2146.

5.

Effects of antiarrhythmic drugs on inappropriate shocks in patients with implantable cardioverter defibrillators.

Lee CH, Nam GB, Park HG, Kim HY, Park KM, Kim J, Choi KJ, Kim YH.

Circ J. 2008 Jan;72(1):102-5.

6.

Antiarrhythmic drugs in patients with implantable cardioverter-defibrillators.

Bollmann A, Husser D, Cannom DS.

Am J Cardiovasc Drugs. 2005;5(6):371-8. Review.

PMID:
16259525
7.

A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators.

Buxton AE, Lee KL, Fisher JD, Josephson ME, Prystowsky EN, Hafley G.

N Engl J Med. 1999 Dec 16;341(25):1882-90. Erratum in: N Engl J Med 2000 Apr 27;342(17):1300.

8.

Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial.

Connolly SJ, Dorian P, Roberts RS, Gent M, Bailin S, Fain ES, Thorpe K, Champagne J, Talajic M, Coutu B, Gronefeld GC, Hohnloser SH; Optimal Pharmacological Therapy in Cardioverter Defibrillator Patients (OPTIC) Investigators.

JAMA. 2006 Jan 11;295(2):165-71.

PMID:
16403928
9.

Long-term efficacy of d/l sotalol in patients with sustained ventricular tachycardia refractory to class I antiarrhythmic drugs.

Kühlkamp V, Mermi J, Mewis C, Braun U, Seipel L.

Eur Heart J. 1995 Nov;16(11):1625-31.

PMID:
8881857
10.

Efficacy and safety of celivarone, with amiodarone as calibrator, in patients with an implantable cardioverter-defibrillator for prevention of implantable cardioverter-defibrillator interventions or death: the ALPHEE study.

Kowey PR, Crijns HJ, Aliot EM, Capucci A, Kulakowski P, Radzik D, Roy D, Connolly SJ, Hohnloser SH; ALPHEE Study Investigators.

Circulation. 2011 Dec 13;124(24):2649-60. doi: 10.1161/CIRCULATIONAHA.111.072561. Epub 2011 Nov 14.

11.

Suppression of sustained ventricular tachyarrhythmias: a comparison of d,l-sotalol with no antiarrhythmic drug treatment.

Kühlkamp V, Mewis C, Mermi J, Bosch RF, Seipel L.

J Am Coll Cardiol. 1999 Jan;33(1):46-52.

12.

Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.

Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, Daubert JP, Higgins SL, Brown MW, Andrews ML; Multicenter Automatic Defibrillator Implantation Trial II Investigators.

N Engl J Med. 2002 Mar 21;346(12):877-83. Epub 2002 Mar 19.

13.

Shocks as predictors of survival in patients with implantable cardioverter-defibrillators.

Pacifico A, Ferlic LL, Cedillo-Salazar FR, Nasir N Jr, Doyle TK, Henry PD.

J Am Coll Cardiol. 1999 Jul;34(1):204-10.

14.

Effect of concomitant antiarrhythmic therapy on survival in patients with implantable cardioverter defibrillators.

Ho AT, Pai SM, Timothy P, Pai RG.

Pacing Clin Electrophysiol. 2005 Jul;28(7):647-53.

PMID:
16008799
15.
16.

Indications for internal cardioverter defibrillator implantation predict time to first shock and the modulating effect of beta-blockers.

Hreybe H, Bedi M, Ezzeddine R, Barrington W, Jain S, Ngwu O, Saba S.

Am Heart J. 2005 Nov;150(5):1064.

PMID:
16290997
17.

Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators.

Moss AJ, Hall WJ, Cannom DS, Daubert JP, Higgins SL, Klein H, Levine JH, Saksena S, Waldo AL, Wilber D, Brown MW, Heo M.

N Engl J Med. 1996 Dec 26;335(26):1933-40.

18.

A multicentre, double-blind randomized crossover comparative study on the efficacy and safety of dofetilide vs sotalol in patients with inducible sustained ventricular tachycardia and ischaemic heart disease.

Boriani G, Lubinski A, Capucci A, Niederle R, Kornacewicz-Jack Z, Wnuk-Wojnar AM, Borggrefe M, Brachmann J, Biffi M, Butrous GS; Ventricular Arrhythmias Dofetilide Investigators.

Eur Heart J. 2001 Dec;22(23):2180-91.

19.

Inductionless or limited shock testing is possible in most patients with implantable cardioverter- defibrillators/cardiac resynchronization therapy defibrillators: results of the multicenter ASSURE Study (Arrhythmia Single Shock Defibrillation Threshold Testing Versus Upper Limit of Vulnerability: Risk Reduction Evaluation With Implantable Cardioverter-Defibrillator Implantations).

Day JD, Doshi RN, Belott P, Birgersdotter-Green U, Behboodikhah M, Ott P, Glatter KA, Tobias S, Frumin H, Lee BK, Merillat J, Wiener I, Wang S, Grogin H, Chun S, Patrawalla R, Crandall B, Osborn JS, Weiss JP, Lappe DL, Neuman S.

Circulation. 2007 May 8;115(18):2382-9. Epub 2007 Apr 30.

20.

Shock occurrence and survival in 241 patients with implantable cardioverter-defibrillator therapy.

Grimm W, Flores BT, Marchlinski FE.

Circulation. 1993 Jun;87(6):1880-8.

PMID:
8504500
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk